Antidote Therapeutics Inc.

Sykesville, MD Residential

UEI
KNPKVDXDCNL9
CAGE
70JF3
Primary NAICS
541714 Research and Development in Biotechnology (except Nanobiotechnology)
SAM.gov registration
Active through

Company facts

Self-certified in SAM.gov
  • For Profit Organization
Entity structure
Corporate Entity (Not Tax Exempt)
SAM.gov registration date
Physical address
1500 Fannie Dorsey Rd, Sykesville, MD 21784, USA
Website
antidotetx.com
Founded
2013
Employees
1-10
Estimated annual revenue
$0-$1M
Industry
  1. Health Care
  2. Pharmaceuticals, Biotechnology & Life Sciences
  3. Pharmaceuticals
SIC code
28 Chemical & Allied Products
Profiles

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Grant awards

Award Agency Obligated Awarded
IND-enabling studies in support of first in human safety studies of a novel anti-nicotine human monoclonal antibody… U01DA058547 National Institute on Drug Abuse (NIH) $35,493,556
Protein engineering of a biologic drug candidate R43DA044064 National Institutes of Health $200,834
Lead optimization and preclinical development of human nicotine-specific mabs R01DA038877 National Institute on Drug Abuse (NIH) $8,453,608

Quick answers

Is Antidote Therapeutics Inc. registered in SAM.gov?

Yes. Antidote Therapeutics Inc.'s SAM.gov registration is active through April 22, 2027.

What is Antidote Therapeutics Inc.'s most recent federal award?

Antidote Therapeutics Inc.'s most recent federal grant award is IND-enabling studies in support of first in human safety studies of a novel anti-nicotine human monoclonal antibody… (U01DA058547), from National Institute on Drug Abuse (NIH), on May 1, 2023.

On GovTribe

See Antidote Therapeutics Inc.'s full federal record

  • Federal grant awards
  • Funding analysis by agency, NAICS and set-aside
  • Similar vendors
Try for free Login